Table 4.
BRAF exon 15 mutations in thyroid tissue adjacent to PTC.
| BRAF Exon 15 Mutations in Thyroid Tissue Adjacent to PTC with the BRAF p.V600E Mutation (n = 19) | ||||
| Total samples (n = 71) | BRAF p.V600E | BRAF non p.V600E | BRAF WT | NA |
| Psammoma Body (n = 3) | 3/71 (4.2%) | - | - | - |
| Follicular Adenoma (n = 1) | - | - | 1/71 (1.4%) | - |
| Oncocytic Follicular Adenoma (n = 2) | - | 1/71 (1.4%) | 1/71 (1.4%) | - |
| Atypical tissue (n = 30) | - | 4/71 (5.6%) | 25/71 (35.2%) | 1/71 (1.4%) |
| Hyperplasia (n = 12) | - | 2/71 (2.8%) | 10/71 (14.1%) | - |
| Normal tissue (n = 23) | - | 1/71 (1.4%) | 21/71 (29.6%) | 1/71 (1.4%) |
| BRAF Exon 15 Mutations in Thyroid Tissue Adjacent to PTC BRAF Exon 15 Wild Type (n = 10) or with BRAF non p.V600E Mutation (n = 1) | ||||
| Total samples (n = 29) | BRAF p.V600E | BRAF non p.V600E | BRAF WT | NA |
| Psammoma Body (n = 3) | - | - | 3/29 (10.3%) | - |
| Follicular Adenoma (n = 3) | - | 1/29 (3.5%) | 2/29 (6.9%) | - |
| Atypical tissue (n = 8) | - | - | 7/29 (24.1%) | 1/29 (3.5%) |
| Hyperplasia (n = 4) | - | - | 4/29 (13.8%) | - |
| Normal tissue (n = 11) | - | - | 11/29 (37.9%) | - |